Skip to content

Study · Randomized controlled trial · n = 84 · 1992

7 results

A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis.

Sternlieb JM, Aronchick CA, Retig JN, Dabezies M, Saunders F, Goosenberg E, Infantolino A, Ionna S, Maislin G, Wright SH

The American journal of gastroenterology1 Nov 1992Cited by 53 (Europe PMC)

PMID1279967 (opens in a new tab)PepBankPUB-01279967
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In ERCP patients, interim analysis showed clinical pancreatitis in 35% with octreotide versus 11% with placebo (p < 0.01).

    In plain wordsIn ERCP patients, pancreatitis occurred in 35% with octreotide versus 11% with placebo.

    Peptide
    Octreotide
    Outcome
    IncreaseClinical pancreatitis
    Study

    n = 84

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms before ERCP and 100 micrograms 45 min after initial dose · intravenous then subcutaneousAs given in this study (human).

    Measurements

    Clinical pancreatitis incidence
    35%
    octreotide (treatment) group, interim analysis
    Clinical pancreatitis incidence
    11%
    placebo (control) group, interim analysis

    Source sentences

    Summary
    Interim analysis in 84 patients revealed an 11% incidence of clinical pancreatitis in the control group and 35% in the treatment group (p < 0.01).
    1 context sentence
    Summary · context
    Eight-four patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) were randomized to receive 100 micrograms of octreotide intravenously immediately prior to ERCP, and 100 micrograms subcutaneously 45 min after the initial dose, or placebo.
  2. 02HumanNon-randomized trialSafety outcome

    Without sphincterotomy, pancreatitis occurred in 10/17 octreotide patients (59%) versus 1/17 placebo patients (6%), RR 10.0 (95% CI 1.4-69.8).

    In plain wordsIn ERCP patients without sphincterotomy, pancreatitis was more frequent with octreotide than placebo.

    Peptide
    Octreotide
    Outcome
    IncreasePancreatitis without sphincterotomy
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms before ERCP and 100 micrograms 45 min after initial dose · intravenous then subcutaneousAs given in this study (human).

    Measurements

    Pancreatitis rate without sphincterotomy
    59%
    octreotide group, 10 of 17 patients
    Pancreatitis rate without sphincterotomy
    6%
    placebo group, 1 of 17 patients
    Relative risk of pancreatitis without sphincterotomy
    10 relative risk
    octreotide versus placebo, 95% CI 1.4-69.8
    95% CI of relative risk
    1.4 to 69.8 relative risk
    octreotide versus placebo, patients without sphincterotomy

    Source sentences

    Summary
    Analysis of group differences stratified by sphincterotomy revealed the following: 1) In patients who did not undergo a sphincterotomy, there was a significantly higher rate of pancreatitis in the treatment group [10/17 (59%) versus 1/17 (6%) RR 10.0 (95% CI 1.4-69.8)].
    1 context sentence
    Summary · context
    Eight-four patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) were randomized to receive 100 micrograms of octreotide intravenously immediately prior to ERCP, and 100 micrograms subcutaneously 45 min after the initial dose, or placebo.
  3. 03HumanNon-randomized trialSafety outcome

    In ERCP patients with sphincterotomy, pancreatitis occurred in 3/20 octreotide patients (15%) versus 4/25 placebo patients (16%), a rate the abstract describes as equal.

    In plain wordsIn ERCP patients with sphincterotomy, pancreatitis occurred in 15% with octreotide versus 16% with placebo.

    Peptide
    Octreotide
    Outcome
    DecreasePancreatitis with sphincterotomy
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms before ERCP and 100 micrograms 45 min after initial dose · intravenous then subcutaneousAs given in this study (human).

    Measurements

    Pancreatitis rate with sphincterotomy
    15%
    octreotide group, 3 of 20 patients
    Pancreatitis rate with sphincterotomy
    16%
    placebo group, 4 of 25 patients

    Source sentences

    Summary
    2) Sphincterotomy reduced the rate of pancreatitis in patients who received octreotide from 10/17 (59% no sphincterotomy), to 3/20 (15% sphincterotomy) (p = 0.01), which equals the rate in patients who received placebo and underwent sphincterotomy [4/25 (16%)].
    1 context sentence
    Summary · context
    Eight-four patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) were randomized to receive 100 micrograms of octreotide intravenously immediately prior to ERCP, and 100 micrograms subcutaneously 45 min after the initial dose, or placebo.
  4. 04HumanNon-randomized trialSafety outcome

    In ERCP-associated pancreatitis, octreotide may have reduced days NPO compared with placebo (p = 0.02).

    In plain wordsIn ERCP-associated pancreatitis, octreotide may have reduced days without oral intake compared with placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseDays NPO
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms before ERCP and 100 micrograms 45 min after initial dose · intravenous then subcutaneousAs given in this study (human).

    Source sentences

    Summary
    3) Although the incidence of pancreatitis was higher in the treatment group, octreotide may reduce the severity of pancreatitis measured by the number of days NPO (Wilcoxon rank sum, p = 0.02), length of stay after ERCP (p = 0.13), the number of days of pain (p = 0.11), and the degree of amylase elevation (p = 0.04).
    1 context sentence
    Summary · context
    Eight-four patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) were randomized to receive 100 micrograms of octreotide intravenously immediately prior to ERCP, and 100 micrograms subcutaneously 45 min after the initial dose, or placebo.
  5. 05HumanNon-randomized trialSafety outcome

    In ERCP-associated pancreatitis, octreotide may reduce severity as measured by length of stay after ERCP compared with placebo (p = 0.13).

    In plain wordsIn pancreatitis after ERCP, octreotide may reduce severity measured by hospital stay compared with placebo (p = 0.13).

    Peptide
    Octreotide
    Outcome
    DecreaseLength of stay after ERCP
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms before ERCP and 100 micrograms 45 min after initial dose · intravenous then subcutaneousAs given in this study (human).

    Source sentences

    Summary
    3) Although the incidence of pancreatitis was higher in the treatment group, octreotide may reduce the severity of pancreatitis measured by the number of days NPO (Wilcoxon rank sum, p = 0.02), length of stay after ERCP (p = 0.13), the number of days of pain (p = 0.11), and the degree of amylase elevation (p = 0.04).
    1 context sentence
    Summary · context
    Eight-four patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) were randomized to receive 100 micrograms of octreotide intravenously immediately prior to ERCP, and 100 micrograms subcutaneously 45 min after the initial dose, or placebo.
  6. 06HumanNon-randomized trialSafety outcome

    In ERCP-associated pancreatitis, octreotide may reduce the number of days of pain compared with placebo (p = 0.11).

    In plain wordsIn ERCP-associated pancreatitis, octreotide may reduce days of pain compared with placebo (p = 0.11).

    Peptide
    Octreotide
    Outcome
    DecreaseDays of pain
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms before ERCP and 100 micrograms 45 min after initial dose · intravenous then subcutaneousAs given in this study (human).

    Source sentences

    Summary
    3) Although the incidence of pancreatitis was higher in the treatment group, octreotide may reduce the severity of pancreatitis measured by the number of days NPO (Wilcoxon rank sum, p = 0.02), length of stay after ERCP (p = 0.13), the number of days of pain (p = 0.11), and the degree of amylase elevation (p = 0.04).
    1 context sentence
    Summary · context
    Eight-four patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) were randomized to receive 100 micrograms of octreotide intravenously immediately prior to ERCP, and 100 micrograms subcutaneously 45 min after the initial dose, or placebo.
  7. 07HumanNon-randomized trialSafety outcome

    In ERCP-associated pancreatitis, octreotide may have reduced amylase elevation compared with placebo (p = 0.04).

    In plain wordsIn ERCP-associated pancreatitis, octreotide may have reduced amylase elevation compared with placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseAmylase elevation
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms before ERCP and 100 micrograms 45 min after initial dose · intravenous then subcutaneousAs given in this study (human).

    Source sentences

    Summary
    3) Although the incidence of pancreatitis was higher in the treatment group, octreotide may reduce the severity of pancreatitis measured by the number of days NPO (Wilcoxon rank sum, p = 0.02), length of stay after ERCP (p = 0.13), the number of days of pain (p = 0.11), and the degree of amylase elevation (p = 0.04).
    1 context sentence
    Summary · context
    Eight-four patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) were randomized to receive 100 micrograms of octreotide intravenously immediately prior to ERCP, and 100 micrograms subcutaneously 45 min after the initial dose, or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.